• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Report: W.Va. Health Officials Thwarted in Effort to Slow OxyContin Epidemic


The healthcare news outlet STAT went to court to unseal records that show officials with West Virginia's state employee health plan were derailed in their early efforts to slow access to OxyContin.

An investigation by STAT has unsealed court records that reveal how Purdue Pharma paid a pharmacy benefits manager, Merck Medco, to prevent health officials in West Virginia from putting limits on which state employees could gain access to OxyContin at the dawn of the opioid epidemic.

The court records, unearthed by STAT writer David Armstrong, show how officials with the state employee health plan spotted all the warning signs and moved to sharply limit prescriptions—they wanted OxyContin to go only to terminally ill cancer patients.

But Purdue Pharma did an end run on the West Virginia health leaders by paying rebates to Merck Medco and pursuing an aggressive strategy to prevent any preauthorization of OxyContin, either for state employees or in Medicaid. STAT filed a motion in May to gain access to records that were sealed in 2004, when Purdue settled with West Virginia for $10 million.

Among the state’s claims: The pharmaceutical company was undermining West Virginia’s early efforts to get the burgeoning opioid crisis under control. “Contrary to the picture of helpfulness and cooperation Purdue attempts to paint, Purdue’s employees were actively and secretly trying to prevent West Virginia from imposing any control on the sale of OxyContin,” the state claimed.

The CDC has chronicled the near perfect match in the trajectory of prescriptions for oxycodone since OxyContin gained FDA approval in 1996, and the rise in deaths related to opioid and heroin abuse. Last December, its report said the 137% rise in drug overdose deaths since 2000 had been fueled almost entirely by the opioid and heroin epidemic, as many turn to the “chemical cousin” of pain pills when they lose access to prescriptions.

According to the CDC, in 2014, West Virginia led the nation in the rate of overdose deaths at 35.5 per 100,000; its neighbors Kentucky and Ohio are among the top 5 states. Unlike many other states, Kentucky refused to take part in early class action settlements and received $24 million in 2015. STAT has also sued to gain access to sealed documents in the Kentucky case.

Officials with the West Virginia state employees’ health plan noticed 2 trends in the early 2000s: starting in 2001, they saw a spike in deaths from oxycodone, and they saw spending for OxyContin climb from $11,000 in 1996, the first year on the market, to $2 million in 2002.

While the state started trying in 2001 to get prior authorization for the drug, it took a full 2 years—and a change in its prescription drug manager—before state health officials succeeded, the STAT report said. By then, West Virginia was, and remains, an epicenter of the opioid epidemic.

In March, the CDC issued new opioid prescribing guidelines for primary care physicians. The guidelines specify that non-opioid therapy is preferred. Purdue Pharma has paid $635 million in fines after pleading guilty to charges that it failed to tell physicians of the drug’s true risks when it marketed the drug.

Related Videos
David Andorsky, MD, Rocky Mountain Cancer Center
Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology
Video 7 - "Future Opportunities in Genitourinary Cancers"
Video 6 - "LITESPARK-003 Trial Insights: Updates from ESMO 2023"
Video 5 - "Key Highlights from EV-302 Study at ESMO 2023"
Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.
Andrew Srisuwananukorn, MD
Dr Jennifer Brown
Related Content
© 2023 MJH Life Sciences
All rights reserved.